Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01421966Phase 3Completed

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

Role: lead

NCT02130310Phase 3Unknown

Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers

Role: lead

NCT01113307Completed

The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds

Role: lead

NCT01038986Completed

A Post-marketing Observational Study of Cell Therapy for Chronic Wounds

Role: lead

All 4 trials loaded